Introduction

Joint wear presents a persistent challenge because articular cartilage heals poorly on its own. Two approaches patients frequently ask about are ChondroFiller and stem cell therapy. These are not straightforwardly competing alternatives: one is a non-surgical collagen scaffold injection, while the other describes a broad class of cell-based biological techniques that can be delivered either by injection or as part of a more comprehensive surgical programme. Understanding the difference matters if you are trying to decide which path is appropriate for your joint.

What Is ChondroFiller?

ChondroFiller Liquid is a type I collagen hydrogel scaffold, CE Class III-marked and manufactured by Meidrix Biomedicals in Germany. It is the material at the centre of both of LCC's cartilage treatment pathways. As an injection, ChondroFiller is delivered via an ultrasound-guided outpatient procedure — no theatre, no general anaesthetic, no incision. Once inside the joint it self-gels in approximately three to five minutes, settling over worn surfaces as a porous, three-dimensional matrix. The scaffold is acellular (cell-free); it works by recruiting the patient's own progenitor cells from surrounding tissue to migrate in and gradually remodel the material towards cartilage. It is supportive and joint-preserving, not a cure or reversal of arthritis, and benefits vary between individuals. A 2023 study in trapeziometacarpal (thumb-base) osteoarthritis reported improvements in pain and grip strength following ChondroFiller use (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., Lavagnolo, U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage, 2023).

Understanding Stem Cell Therapy

Stem cell therapy — more precisely, mesenchymal stem cell or medicinal signalling cell (MSC) therapy — involves harvesting progenitor cells from the patient's own bone marrow (as bone marrow aspirate concentrate, BMAC) or from micro-fragmented fat tissue (mFAT), then reintroducing those cells into the joint environment. MSCs do not convert directly into cartilage; rather, they release trophic and immunomodulatory signals that can reduce inflammation and create conditions more favourable for tissue repair. The process requires at least one additional procedural step beyond a standard injection, and results depend on cell yield, defect characteristics, and individual biology. Neither MSC therapy alone nor ChondroFiller alone guarantees cartilage regeneration, and any claim of cure should be treated with caution.

How LCC Approaches These Options: Two Distinct Pathways

At London Cartilage Clinic, ChondroFiller and MSC-level biological support are not simply two alternatives placed side by side. They sit within two distinct treatment pathways, and understanding this distinction is important when comparing them.

The ChondroFiller Injection (Non-Surgical Pathway)

For accessible lesions and smaller joints, ChondroFiller can be delivered as a stand-alone ultrasound-guided injection in an outpatient setting. This is entirely non-surgical: no theatre, no anaesthetic, and a straightforward recovery. The collagen scaffold provides a regenerative layer over worn cartilage, acting as a supportive matrix and cushion. This pathway suits patients who prefer to avoid surgery, or whose lesion is not large enough to warrant an operative approach.

The Liquid Cartilage Surgical Protocol (Surgical Pathway)

For larger or load-bearing cartilage defects — typically in the knee, hip, shoulder, or ankle — Professor Paul Y. F. Lee performs the Lee Liquid Cartilage Protocol (LLC Protocol): a keyhole (arthroscopic), minimally invasive surgical procedure conducted in theatre under anaesthetic. This is genuine surgery, not an injection. The LLC Protocol delivers the ChondroFiller scaffold under dry arthroscopic conditions, combined with biological adjuncts including platelet-rich fibrin (PRF), platelet-rich plasma (PRP), and tranexamic acid. Where clinically indicated, the patient's own mesenchymal stem cells — sourced from bone marrow aspirate concentrate (BMAC) or micro-fragmented fat (mFAT) — are added directly at the time of surgery to enhance the regenerative environment. Recovery is structured: protected weight-bearing for the first two to four weeks, progressive physiotherapy through weeks four to eight, functional loading at two to four months, and return-to-sport progression from around six months, with scaffold remodelling continuing over one to two years.

The significance of this distinction is that the LLC Protocol already incorporates the MSC biological enhancement within its surgical framework when the indication exists. A patient asking about stem cell therapy for a significant cartilage defect may therefore be better served by the LLC Protocol — where cell therapy and a stable scaffold are combined in a single, controlled surgical environment — rather than a standalone injection of either material.

Comparing the Options

Both the ChondroFiller injection and the Liquid Cartilage surgical protocol aim to support joint preservation, but they differ substantially in complexity, invasiveness, and the scale of defect they address.

• ChondroFiller injection: non-surgical, single ultrasound-guided outpatient procedure, no cell harvesting, suited to accessible lesions and smaller joints, minimal recovery.
• Liquid Cartilage (LLC Protocol): keyhole surgery in theatre, combines ChondroFiller scaffold with biologics (PRF, PRP, TXA) and optional MSCs, suited to larger or load-bearing defects, structured rehabilitation over months.
• Standalone stem cell injection: cell harvesting step required, multi-step process, no stable scaffold support, evidence base still evolving for focal cartilage defects.
• Neither approach guarantees cartilage regrowth; benefits vary between patients, defects, and joints.

Who Is Best Suited to Each Option?

The right pathway depends on the joint involved, the size and grade of the cartilage defect, your age, overall health, activity goals, and your tolerance for surgical recovery. The ChondroFiller injection may suit patients with osteoarthritis or localised joint wear who want a non-surgical option and have an accessible defect — including joints such as the knee, hip, thumb, or ankle. The LLC Protocol is more appropriate for patients with larger, load-bearing defects where a combined scaffold-and-biologics surgical approach offers a more controlled regenerative environment. An individual assessment is necessary before any recommendation can be made.

Conclusion

The ChondroFiller injection and stem cell therapy are not a straightforward either/or comparison. The more complete picture is of two treatment pathways: a non-surgical collagen scaffold injection for accessible lesions, and the Liquid Cartilage surgical protocol for more significant defects, which can incorporate MSC biological support within the same keyhole procedure when indicated. For individual advice, a specialist consultation is needed to assess which pathway — or combination — aligns with your specific joint, defect, and goals. London Cartilage Clinic offers assessment by Professor Paul Lee, who developed the LLC Protocol and assesses both injection and surgical candidates from the Harley Street clinic.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., Lavagnolo, U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage, 2023.